ABSTRACT
Spot-urinary biomarkers are essential for medical, epidemiological, and environmental research. However, they are affected by hydration-dependent diuresis, requiring precise dilution adjustments. Traditional methods, like conventional creatinine correction (CCRC), have limitations and introduce errors due to residual diuresis dependence. To address this, the WHO recommends a valid creatinine (CRN) range of 0.3-3 g/L. The present study introduces a novel numerical variable power functional CRN correction method (V-PFCRC). It was developed using 5553 spot urinary samples for total weight arsenic from a diverse population with generally low background exposure to inorganic arsenic from drinking water. The innovative V-PFCRC formula normalizes analytes (A) to 1 g/L CRN using uncorrected analyte levels and two analyte-specific coefficients, c and d:
When applied to spot urinary arsenic, iodine, cesium, molybdenum, strontium, and zinc, the V-PFCRC method significantly reduced residual CRN bias. It performed better than uncorrected, conventionally (CCRC), and simple power functionally CRN-corrected (S-PFCRC) urine samples. V-PFCRC enhanced CRN-bias removal in entire datasets and within seven separately analyzed analyte levels (septiles), adequately compensating for non-linear, exposure-differentiated skews, including complex metabolic and excretory interactions between analytes and CRN. These advancements were supported by improved blood-urine correlations for iodine and arsenic in both sexes, suggesting a more accurate representation of supply and exposure than traditional urinary dilution corrections. The results underscore the superior performance of the V-PFCRC method in adjusting for hydration-dependent variability, surpassing traditional correction methods. The resource-efficient and versatile V-PFCRC method is easy to implement and holds immense potential for broader applications in various scientific and medical fields. This study advocates for the wider adoption of V-PFCRC to enhance the accuracy and reliability of urinary biomarkers, ensuring superior diagnostic and research outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethic committee of North west - and Central Switzerland (EKNZ), Hebelstrasse 53, 4056 Basel, Tel. 061 268 13 50, Fax 061 268 13 51 Email: eknz{at}bs.ch, gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Tab. 3 contained a sign error of the female coefficient c of the result mode 5. It has the value -0.111 instead of 0.111.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
7. Abbreviations
- As
- Arsenic
- CCRC
- Conventional Creatinine Correction (by calculating the ratio Analyte/CRN)
- CRN
- Urinary Creatinine Concentration (g/L)
- DMA
- Dimethylarsinic acid
- ICP-MS
- Inductively Coupled Plasma Mass Spectrometry
- IQR
- Interquartile Range
- MMA
- Monomethylarsonic acid
- V-PFCRC
- Variable Power-Functional Creatinine Correction (using a variable exponent b)
- SAME
- S-Adenosyl-Methionine
- SDAE
- Systemic Dilution Adjustment Error
- S-PFCRC
- Simple Power-functional Creatinine Correction (using a fixed exponent b)
- uAsC
- Conventionally Creatinine-Corrected Urinary Arsenic (µg/g CRN)
- uAsN
- Power-functionally adjusted urinary arsenic, normalized to µg/1g CRN
- uAsUC
- Uncorrected urinary arsenic (µg/L)
- UC
- Uncorrected Urine Results (µg/L)
- UFR
- Urinary Flow Rate, Urine Excretion/Time (ml/min)
